ArticleExperimental and therapeutic medicine2026
Inhibitory effects of spermidine on lipopolysaccharide-induced inflammation in RAW 264.7 cells.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spermidine (SPD) is a naturally occurring polyamine with anti-inflammatory and antioxidant properties. Given the pivotal role of macrophages in inflammatory pathogenesis (such as rheumatoid arthritis and autoimmune encephalomyelitis), the present study hypothesized that SPD exerts its anti-inflammatory effects by suppressing macrophage polarization. Briefly, RAW 264.7 cells were activated using lipopolysaccharide (LPS) and were treated with a vehicle control (complete DMEM) or varying SPD concentrations. The ratio of M1 and M2 macrophages in each group was determined using flow cytometry. Inflammatory gene expression and cytokine levels were determined using reverse transcription quantitative PCR and ELISA. The levels of NF-κB pathway-associated proteins were measured through western blotting. The findings revealed that the proportion of M1 cells gradually decreased with increasing SPD concentrations. In LPS-stimulated RAW 264.7 cells, SPD markedly decreased the expression of M1 marker genes and notably increased that of M2 marker genes. Furthermore, SPD decreased IL-6 levels and increased IL-10 levels. In addition, the levels of phosphorylated (p)-p65 and p-IκBα, which are NF-κB pathway-associated proteins, were markedly decreased after 24 h of SPD treatment. Overall, SPD treatment inhibited LPS-induced M1 polarization, reduced pro-inflammatory gene/cytokine expression and enhanced anti-inflammatory markers, potentially through NF-κB pathway modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.